CommercialPrior AuthMedium impact
Testosterone Replacement Therapy
Blue Cross & Blue Shield of Mississippi·MS · Family Medicine, Internal Medicine, Endocrinology +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their testosterone replacement therapy policy, requiring prior authorization for all non-injectable testosterone formulations (gels, pellets, nasal, oral) while injectable forms remain prior auth-free. Specific quantity limits and coverage criteria have been established for different testosterone products.
Action Required
Immediately: Billing team must implement prior authorization requirements for all non-injectable testosterone products including gels (Androgel, Testim, Fortesta, Vogelxo), pellets (Testopel), nasal gel (Natesto), and oral forms before prescribing or billing. Update system to flag that injectable testosterone cypionate and enanthate do NOT require prior auth. Train providers on new coverage criteria requiring documented hypogonadism diagnosis, morning testosterone lab results, and failed trials of injectable forms before approving alternative formulations. Claims for non-injectable forms without prior authorization will be denied.